

**To:** Dr. Kevin Niswender; Dr. Pruett  
**From:** Chad T. Mansfield (ISSA-CPT)  
**Subject:** Case framing + rationale for tirzepatide renewal (data attached)

Dear Drs. Niswender and Pruett,

Thank you for supervising my 72-hour fast and for your time. I assembled a concise case framing that integrates the fast results, subsequent labs (11/12/2025), and prior response to tirzepatide.

- The physiology during fasting showed persistent hyperglycemia with suppressed ketogenesis that only shifted after quetiapine, suggesting central/ANS-amplified hepatic insulin resistance and impaired mitochondrial substrate switching.
- Historically, tirzepatide normalized fasting glucose and improved function; metformin did not.
- I included a brief workup plan and figures (timelines and, pending export, device-based trends).

Attachments/Repo items: - docs/vanderbilt\_case\_framing.md - full case framing  
- docs/tirzepatide\_rationale.md - renewal rationale  
- figures/timeline\_fast\_case.png, figures/three\_lane\_timeline.png  
- data/labs\_2025-11-12.csv, data/labs\_trend.csv

I'm grateful for your consideration and guidance on confirmatory testing and next steps.

Respectfully,

**Chad T. Mansfield**

ISSA-CPT | Patient-researcher